Karyopharm FY2022 total revenue $157.1M, net loss $165.3M; FY2023 guidance $160-175M

Karyopharm Therapeutics Inc.

2022-FY EPS reported -$2.02 revenue$157,074,000

U.S. XPOVIO net product revenue $120.4M in FY2022, up 22% YoY from $98.4M.
FY2022 net loss $165.3M ($2.02/share) vs net loss $124.1M ($1.65/share) in 2021.
Cash, cash equivalents and investments $279.7M at Dec 31, 2022; $165M private placement extends cash runway into late 2025.
FY2023 guidance: total revenue $160-175M, XPOVIO net product revenue $125-140M, non-GAAP R&D+SG&A $260-280M.
Initiated Phase 3 selinexor maintenance in TP53 wild-type endometrial cancer; Phase 1 MF and Phase 2 MDS data due 1H 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Karyopharm Therapeutics Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue Total revenue for the fourth quarter of 2022 was $33.6 million, compared to $126.3 million for the fourth quarter of 202. Guidance initiated.

Period: the fourth quarter and full year ended December 31, 2022
Revenue: Total revenue for the fourth quarter of 2022 was $33.6 million, compared to $126.3 million for the fourth quarter of 202
Guidance: initiated
Result: reported results

Exact text from the filing

On February 15, 2023, Karyopharm Therapeutics Inc. announced its financial results for the fourth quarter and full year ended December 31, 2022 and will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Karyopharm Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-039757

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.